drugset / Trial / NCT03229876
Safety and Efficacy Evaluation of CD19-UCART
Suspended
20 enrolled
Bioray Laboratories
First Affiliated Hospital of Zhejiang University · collabSecond Xiangya Hospital of Central South University · collabThe First Affiliated Hospital of Zhengzhou University · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of ascending doses of CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2023-12-15
- Completion
- 2023-12-30
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-UCART | Cell therapy | 1e+06 cells/kg | Other |
| Subject | CD19-UCART | Cell therapy | 2.5e+06 cells/kg | Other |
| Subject | CD19-UCART | Cell therapy | 5.5e+06 cells/kg | Other |